Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis - Concepedia

Concepedia

Publication | Open Access

Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis

DOI Full Paper Access

195

Citations

22

References

2016

Year

Koji Sasaki, Elias Jabbour, Farhad Ravandi, Nicholas J. Short, Deborah A. Thomas, Guillermo Garcia‐Manero, Naval Daver, Tapan M. Kadia, Marina Konopleva, Nitin Jain,

Abstract

The clinical outcome of patients treated with HCVAD plus ponatinib appears to be superior to that of patients treated with HCVAD plus dasatinib among individuals with Ph+ ALL. Cancer 2016;122:3650-6. © 2016 American Cancer Society.

References

	Year	Citations

Page 1